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Abstract:  Ribosome-inactivating proteins (RIPs) are EC3.2.32.22 N-glycosidases that 
recognize a universally conserved stem-loop structure in 23S/25S/28S rRNA, depurinating 
a single adenine (A4324 in rat) and irreversibly blocking protein translation, leading finally 
to cell death of intoxicated mammalian cells. Ricin, the plant RIP prototype that comprises 
a catalytic A subunit linked to a galactose-binding lectin B subunit to allow cell surface 
binding and toxin entry in most mammalian cells, shows a potency in the picomolar range. 
The most promising way to exploit plant RIPs as weapons against cancer cells is either by 
designing molecules in which the toxic domains are linked to selective tumor targeting 
domains or directly delivered as suicide genes for cancer gene therapy. Here, we will 
provide a comprehensive picture of plant RIPs and discuss successful designs and features 
of chimeric molecules having therapeutic potential. 
Keywords:  ribosome-inactivating proteins; cancer immunotherapy; ITs; vascular leak 
syndrome; recombinant expression; fusion toxins; single chain antibody variable fragments; 
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1. Ribosome Inactivating Proteins and Plant Defense Mechanism(s)  
Ribosome-inactivating proteins (RIPs) are toxins able to specifically and irreversibly inhibit protein 
translation. Most plants and bacterial RIPs, such as Shiga and Shiga-like toxins from the bacteria 
Shigella dysenteriae and the Shigatoxigenic group of Escherichia coli (which include other 
enterohemorrhagic E. coli strains), exert their toxic effects through binding to the large 60S ribosomal 
subunit on which they act as an N-glycosidase by specifically cleaving the adenine base A4324 in  
the 28S ribosomal rRNA subunit. This results in the inability of the ribosome to bind elongation   
factor 2, thus blocking protein translation [1,2]. RIPs are widely distributed in nature but are found 
predominantly in plants, bacteria and fungi. Besides their activity on rRNA, certain RIPs display a 
variety of antimicrobial activities in vitro, such as antifungal, antibacterial, and broad-spectrum   
anti-viral activities against both human and animal viruses, including the human immunodeficiency 
virus, HIV [3].  
RIPs from plants have been classified into three main types: Type I is composed of a single 
polypeptide chain of approximately 30 KDa, Type II is a heterodimer consisting of an A chain, 
functionally equivalent to the Type I polypeptide [4], linked to a B subunit, endowed with   
lectin-binding properties [5] (Figure 1), while Type III are synthesized as inactive precursors (ProRIPs) 
that require proteolytic processing events to form an active RIP [6] and are not in use for therapeutic 
purposes. Besides their well characterized activity of depurinating ribosomes at the “sarcin/ricin loop” 
in vitro (see below), their physiological function(s) are not yet completely understood and the question 
as to why some plants should synthesize RIPs remains still open. Different RIPs have been reported 
from about 50 plant species covering 17 families. Some families include many RIP-producing species, 
particularly Cucurbitaceae, Euphorbiaceae, Poaceae, and families belonging to the superorder 
Caryophyllales [7,8]. 
Figure 1. Schematic representation of the mature forms of Type I (A) and Type II (B) plant 
Ribosome-inactivating proteins (RIPs). Comparison between the mature forms of a Type I 
(RIP) (A), such as saporin, composed only of a catalytically active A domain, and that of a 
Type II RIP (B), such as ricin, in which the active domain is connected to a lectin binding 
B chain domain by a disulfide bond. 
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Several biotechnological approaches have been applied to reveal a potentially important role of 
RIPs in plant defense ever since crude extracts of pokeweed leaves were first shown to have inhibitory 
activity against viral infections. To exploit antimicrobial activity, different RIPs, including pokeweed 
antiviral protein (PAP), trichosanthin (TC) from Trichosanthes kirilowii Maxim., and the antiviral 
protein from Phytolacca insularis Nakai, have been expressed in transgenic plants successfully,leading 
to resistance against various viral and/or fungal proteins [9–12].  
Recently, two distinct saporin types from Saponaria officinalis L., saporin-L (leaf-like) and   
saporin-S (seed-like) isoforms were purified from the intra- and extracellular fractions of soapwort 
leaves. These isoforms differed in toxicity, molecular mass and amino acid composition. Differential 
expression of these saporin genes during leaf development and upon wounding and abscisic acid 
treatment has been described, indicating that different RIP isoforms may play diversified roles during 
plant stress responses [13]. The antiviral role of RIPs in plants is postulated on the basis of their 
enzymatic activity and selective compartimentalization [13–16]. RIPs may potentially inactivate 
ribosomes in the same cells in which they are synthesized and they are found sequestered into 
vacuoles, protein bodies, or cell walls [13,14]. It is suggested that when plants are wounded, for 
instance during viral infection, RIPs may be released from their intracellular compartments. This 
would prevent viral replication at an early stage by inactivating the cell protein synthesis machinery 
and leading to autonomous cell death [3,17]. However, the exact role of RIPs in planta still remains 
elusive, since also not all plant species express these toxins. In addition, most RIP-expressing plants 
present multigene families that seem to be under a clear selective pressure. A recent publication from 
the Craig Venter Institute revealed that whereas oil metabolism genes were found in single copy, the 
ricin gene family was even more extensive than previously thought, implying a strong selective 
pressure to maintain these ricin-like genes [18]. Among 25 geographically different castor bean plants, 
the presence of six ricin-like loci was confirmed, which shared 62.9–96.3% nucleotide identity with 
intact A-chains of the preproricin gene [19]. Replacement mutations preserved the 12 amino acids 
known to affect catalysis and electrostatic interactions of the native protein toxin, suggesting that 
functional divergence among alleles was only minimal. Nucleotide polymorphism was maintained but 
included an excess of rare silent mutations much greater than what would be predicted by a neutral 
equilibrium model [19].  
Synthesizing an endoplasmic reticulum (ER)-targeted inactive precursor polypeptide is most likely 
the mechanism by which Ricinus communis L. cells can avoid intoxication by the endogenously 
synthesized toxin [20,21]. In addition, it has been shown that tobacco protoplasts can also safely 
synthesize the full length ricin precursor without any detrimental effect on host protein synthesis [22]. 
In contrast, the expression of an orphan secretory ricin toxic A chain (RTA) polypeptide results in the  
etro-translocation of RTA to the cytosol followed by inhibition of protein synthesis in the tobacco 
protoplasts, making RTA the most studied plant ER-associated degradation (ERAD) substrate, with the 
AAA-ATPase Cdc48/p97 being recently identified as an extraction motor for this toxin from the plant 
ER [22–25]. Little is known about the synthesis of Type-I precursor polypeptides in planta. Since 
several Type I RIPs are active towards “conspecific” ribosomes, and because of this observation, the 
inefficient targeting or translocation of Type I RIPs can potentially lead to self-intoxication, and 
therefore, mechanisms must be in place to prevent the unregulated accumulation of the active enzymes 
in the cytosolic compartment. In addition, this characteristic has led to the idea that these enzymes Toxins 2010, 2   2702 
 
could play an important role in blocking the spread of certain pathogens by causing the death of 
infected cells [26,27]. Following the local suicide hypothesis [15,28], plant cells undergoing plasma 
membrane breaching by a virus would allow entry of apoplast-located toxins. This localized cell death 
would concomitantly block replication and the systemic spread of the virus load throughout the plant. 
In such a model, prior accumulation of the RIPs within the apoplast would be crucial. However, this 
mechanism was criticized because protein synthesis in damaged cells would be stopped during viral 
infection [6]. As an alternative, it has been suggested that specific mechanisms might regulate the 
access of a particular RIP to cytosolic ribosomes only when the plant cell becomes infected. The Iris 
RIPs, as an example, protect plants from local but not from systemic infections, indicating that their 
antiviral activity is effective only in the initially infected cells [29]. Specific signals may lead to a 
change in the subcellular localization of the toxin, or to the degradation of a putative RIP   
inhibitor [30]. One of these mechanisms might be embedded in the plant signal peptide, as we have 
recently demonstrated in the case of saporin [31] where cleavage of the signal peptide was found to 
represent an activation step in the saporin biosynthetic pathway. In vivo, mutations affecting signal 
peptide cleavage could clearly reduce (although not fully eliminate) host cell toxicity. 
Stress-sensitive abortion of co-translational traslocation may provide a novel pre-emptive quality 
control pathway to regulate protein entry into the secretory compartment [32] and would lead in the 
case of saporin to activate the newly synthesized saporin precursor, allowing for its partial insertion 
into the ER to undergo signal peptide cleavage, and thus toxin activation. 
2. Biochemical Characteristics 
2.1. RIP Toxic Domains: Saporin Isoforms, RTA and 3-D Structures of Type I RIPs  
Saporin collectively identifies a family of RIP isoforms that accumulate in different soapwort 
(Saponaria officinalis L.) tissues. Mixtures of closely related isoforms and several cDNA and genomic 
clones have been isolated. SO6 saporin or saporin-6 represents the major HPLC peak (peak 6) of 
purified seed protein and constitutes about 7% of the total proteins. For a comprehensive detailed 
description of the saporin isoforms investigated so far, please refer to [33]. Seed protein sequencing 
revealed heterogeneity at two positions, with either an aspartic or a glutamic acid in position 48, and 
either lysine or arginine present in position 91, indicating that the SO6 peak contains a set of closely 
related saporin isoforms. In fact, RP-HPLC analysis confirmed the presence of at least three different 
isoforms in SO6 preparations while recombinant expression of single seed-like isoforms demonstrated 
the same RIP activity, except for a leaf-derived isoform [34]. While some characteristics of the saporin 
proteins, such as key catalytic residues and overall three-dimensional fold, are shared with RTA and 
the other known crystalized RIPs, other biochemical features clearly differ among Type I plant RIPs 
and RTA. The sequence identity is low between RTA and Type I RIPs; RTA has only two lysine 
residues while lysine residues can account for up to 10% total amino acids in Type I RIPs. Indeed, 
amino acid sequence among type I RIPs and RTA may vary widely as can be seen by the alignment of 
some selected Type I RIPs in Figure 2, despite that all the crystallized RIPs have been shown to share a 
common three-dimensional fold, as can be estimated by the superimposition of the 3D structures of 
several Type I RIPs and RTA (Figure 3). Toxins 2010, 2   2703 
 
Figure 2. Amino acid sequence alignment of different type I RIPs compared to Ricin (A chain). 
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Figure 3. Three-dimensional structures of different Type I RIPs and ricin A chain. 
Superimposition of secondary structure elements of Ricin A chain (PDB code 1J1M), 
Thricosanthin (PDB code 1J4G), Saporin (PDB code 1QI7), Dianthin (PDB code 1RL0), 
PAP (PDB code 1PAF), Bouganin (PDB code 3CTK), and Gelonin (PDB code 3KTZ). 
Five conserved residues in the active site clefts corresponding to Saporin residues Tyr72, 
Tyr120, Glu176, Arg179, Trp208 are highlighted in magenta while the other colors refer to 
RIPs as following: Ricin in blue, Thricosanthin in red, PAP in green, Bouganin in yellow, 
Gelonin in orange. Crystal structures with high homology to the RIP sequences in Figure 2 
have been superimposed by the SSM algorithm and this figure was produced by PyMOL. 
 
 
Only 22% of residues are conserved between RTA and saporin SO6, about 15% are shared between 
the latter and TC, while RTA and gelonin from Gelonium multiflorum A. Juss. share approximately 30% 
sequence identity [35]. On the contrary, a high degree of sequence identity (about 80%) is found 
between saporin SO6 and dianthin from Dianthus caryophyllus L., both of which are synthesized by 
plants belonging to the same subfamily of the Caryiophyllaceae family. The three-dimensional 
structures of RTA [36] and different Type I RIPs, including PAP [37], TC [38], gelonin [39], seed 
saporin SO6 [40] and, more recently, dianthin [41] have been determined, and demonstrate that RTA 
and Type I RIPs all share the common “RIP fold” characterized by the presence of two major domains: 
an N-terminal domain, which is mainly beta-stranded, and a C-terminal domain that is predominantly 
alpha–helical. Insertions and deletions, as compared to PAP, Momordin from Momordica charantia L. 
and RTA, lie mainly in random coil regions. Several residues are highly conserved among RIPs, Toxins 2010, 2   2705 
 
including Tyr80, Tyr123, and the key active site residues Glu177, Arg180, and Trp211 of RTA   
(Figures 2 and 3). 
In Figure 2, residues highlighted in yellow correspond to conserved residues present in the active 
site (Tyr72, Tyr120, Glu176, Arg179, and Trp208 in Saporin). The sequence identities between Ricin A 
chain and the Type I RIPs analyzed are the following: Dianthin 19%, PAP 29%, Bouganin 29%, 
Thricosanthin 35%, Gelonin 30%. The sequence alignments have been performed with ClustalW. 
Asterisks indicate other conserved residues. 
2.2. Interaction with Substrates and Catalytic Activity  
The depurinating N-glycosidase mechanism of RTA is well understood. The target adenine in the 
substrate (28S rRNA) is inserted inside the catalytic cleft, with the aromatic ring becoming 
sandwiched between Tyr80 and Tyr123 with Arg180 partially or fully protonating N3 of the ribose 
ring, thus inducing a positive charge stabilization of the intermediate ribose by Glu177. Then, a water 
molecule is activated, probably by Glu177 [42], inducing nucleophilic attack to the N9-C1 glycosidic 
bond linking adenine to the ribose ring, then finally releasing free A4324. For most of the 3D 
structures, the Tyr80 aromatic ring is almost parallel to that of Tyr123/120, as required to form a stack 
with the adenine of the substrate, while for Ricin and gelonin Tyr80 is oriented in such a way that the 
hydroxyl group forms a hydrogen bond with the Gly121 carbonyl group (note the blue and orange 
residues, respectively, in Figure 3). For all the considered 3D structures, crystallographic analysis 
revealed a higher thermal parameter for the first catalytic residue with respect to the other   
conserved residues, indicating that it could work as a moving door for the adenine entering in the 
catalytic site [43].  
Most of the secondary structural elements are comparable and superimposable between RIPs, 
including the catalytic cleft, as seen above, while the deviations are seen mainly in some   
surface-located loop regions. For instance, the loop connecting strands beta-7 and beta-8 located at the 
C-terminus is variable in length among RIPs, being very short in saporin SO6 [40] and in dianthin 30, 
but longer in PAP and RTA. This region contains several lysine residues, which seem to be involved in 
the molecular recognition of the ribosome. The reduced length of this loop could determine an 
increased accessibility to the substrate for both saporin and dianthin. The interaction between RIPs and 
the ribosomal proteins is essential to achieve optimal enzymatic activity; RTA can be cross-linked to 
mammalian ribosomal proteins L9 and L10e [43], while PAP recognizes L3 [44]. Chemical   
cross-linking studies suggest that at least one 30 kDa ribosomal protein from the 60S yeast ribosomal 
subunit comes into contact with saporin [45] by a region within the C-terminus which includes three 
lysine residues in positions 220, 226 and 234 [40]. Also in TC, three key basic residues (Lys173, 
Arg174 and Lys177), located at the C-terminal domain, are involved in binding to ribosomal   
proteins [46]. A recent study confirms that electrostatic interactions play a crucial role in facilitating 
several RIPs, endowed with a net surface positive charge, in finding their ribosomal target sites [47], 
since the latter exhibit a negative electrostatic potential, arising from both the negatively charged 
phosphodiester backbone and from conserved solvent-exposed acidic patches on the ribosomal 
proteins. In terms of their catalytic activity, RIPs were officially denominated “rRNA N-glycosidases” 
(EC 3.2.2.22) [48] as they removed the specific adenine residue (A4324 in rat liver rRNA) located in Toxins 2010, 2   2706 
 
the universally conserved GAGA-tetraloop, also known as the alpha sarcin/ricin loop, present   
in 23/26/28S rRNA [49]. Some RIPs, however, have been reported to remove more than one adenine 
residue per ribosome [50], thus also possessing a polynucleotide: adenosine glycosidase (PNAG) 
activity [51] and, as better detailed below, they have been also reported to depurinate DNA [52]   
and other polynucleotides. The RIP active site includes a dozen of residues that are conserved among 
RIP family members, which include Tyr72, Tyr120, Glu176, Arg179, and Trp208 in saporin-6   
(see Figure 2), and systematic studies were performed by mutating these residues, shedding light on 
their contribution to the catalytic activity of RTA [33] and Type I saporin [52]. Tyr72 mutation has a 
stronger impact on saporin-6 catalytic activity than Tyr120 mutation. Both Glu176 and Arg179 in 
saporin-6 (and Glu177 and Arg180 in RTA) are thought to be directly involved in catalysis. However, 
while the Glu176 mutant was 20-fold less active than wild-type in inhibiting translation in a 
reticulocyte lysate, the Arg179 mutant was 200-fold less active [52]. A complete loss of in vitro and  
in vivo saporin cytotoxicity can be achieved when Glu176 and Arg179 are mutated to lysine and 
glutamine residues, respectively. This double mutant (termed KQ) is, indeed, devoid of the detrimental 
effects associated with RIP expression in several hosts [31,53–54]. Interestingly, mutation of Trp208 in 
saporin did not impair its in vitro enzymatic activity and cytotoxicity [52] but this same residue was 
seen to be crucial for the structural integrity of PAP [55]. 
2.3. Extra Enzymatic Activities 
More than 50 RIPs have been reported to depurinate other nucleic acids such as poly(A) RNA, 
herring sperm DNA, and capped RNAs and SO6  to depurinate a variety of polynucleotides   
[50,51,56–58]. However, the activity of seed-extracted SO6 was found to vary between different 
batches or experiments when poly(A) or viral RNAs were used as substrates [51], while recombinant 
single saporin isoforms [34] were instead found essentially inactive on poly(A) and viral RNAs, but 
active on rRNA at pH 4.0 [51]. In addition, it was also reported that some RIPs could hydrolize  
single-stranded and double-stranded DNA [52,55,57–58] in certain conditions. A comparison of the 
PNAG activity of bouganin, lychnin, dianthin 30, PAP-R, mormordin I, RTA and saporin-6 indicated 
that saporin-6 released the highest number of adenine molecules from rat ribosomes and poly(A), 
while its efficiency was similar to dianthin 30, bouganin and PAP-R on herring sperm DNA. At the 
same time, saporin-6 was found to be the most active toxin in inhibiting protein synthesis. A detailed 
structural analysis of the N- and C-terminal domains indicated that the efficiency of saporin-6 on 
various polynucleotides could be ascribed to a negative electrostatic surface potential at the active site 
and several exposed positively charged residues in the region around that site. These two conditions, 
which are not present at the same time in the other examined RIPs, would guarantee an efficient 
interaction with the substrate and efficient catalysis [59]. The debate is still open as to whether or not 
RIPs possess enzymatic activities other than N-glycosidase or PNAG, such as RNAase and/or DNAase 
activities [6]. Some RIPs have been even reported to have superoxidismutase (SOD) [60] and ricin A 
phospholipase [61] activity. Interestingly, although SOD activity reported for camphorin   
(from  C. camphora) has not been independently confirmed, a 26-KDa RIP-like protein from   
Nicotiana tabacum has shown SOD activity in addition to an N-glycosidase activity [62]. In plants, 
both enzymatic activities may play a central role in defense response mechanisms and therefore it was Toxins 2010, 2   2707 
 
tempting to speculate that the plant may differentially switch these activities, exerted by the same 
protein, upon specific environmental/biological requirements. The strong spatial similarities of type I 
RIPs, as shown in Figure 3, might suggest that different specificities/enzymatic activities may only 
reside in a limited number of polypeptide areas and a rigorous assessment of whether the latter may 
contribute to altered activity would require either site-directed mutagenesis or protein domain 
swapping experiments. 
In conclusion, the biological significance of the activity against rRNA at sites different from the 
alpha-sarcin one and on substrates other than the ribosome (DNA, viral RNA, poly(A), RNA), remains 
to be firmly established. Like RTA [48,49], seed extracted saporin has been recently found to release a 
single adenine from 80S ribosomes [63]. In addition, when mamalian cells were exposed to   
seed-extracted saporin and rRNA was extracted from intoxicated cells, rRNA was found to be 
depurinated at a single site, most likely the one corresponding to the alpha sarcin-ricin target [64]. 
Removal of a second adenine residue or more adenine residues has also been reported for saporin-6 
and saporin L1, respectively [59,63]. Analysis of the in vivo activity of other saporin isoforms   
(such as L1) [63] will be required to assess whether multiple depurination events play any major role 
in the mammalian cell’s intoxication process. In addition to the PNAG activities reported above, 
concerning the DNase-like activities [52,57] proposed for the type I RIPs, several pieces of evidence 
indicate that the DNase activity associated with ricin, saporin (and possibly with other type I RIPs) 
may be instead due to nuclease contamination [6,54,65–66]. 
3. RIP Intoxication Routes in Mammalian Cells 
Ricin dimers efficiently enter target mammalian cells by receptor-mediated endocytosis, thanks to 
the presence of the lectin B domain that binds to exposed galactose residues, then the dimers undergo 
retrograde transport from the Golgi complex to the ER [21,67] where the catalytic A chain (RTA) is 
most likely reductively separated from the cell-binding B chain domain [68]. Free RTA then mimicks 
ER-associated degradation (ERAD) substrates to enter the cytosol [67] and may escape degradation 
also due to its low lysine content [69], thus inactivating cytosolic ribosomes and finally leading to 
apoptotic cell death (see Figure 4). Much less attention has been devoted to the study of the pathway(s) 
followed by saporin, and other Type I RIPs in general, during the mammalian cell intoxication process. 
For instance, saporin cytotoxicity varies in a wide range, with concentrations inhibiting protein 
synthesis by 50% (IC50) changing from nanomolar to micromolar, depending on the cell lines 
investigated [33]. The alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein 
(LRP1) binds saporin in vitro and mediates saporin internalization in human monocytes and in 
fibroblasts [33–34]. The LDL receptor family includes seven closely related family members: LDLR, 
the very-low-density lipoprotein (VLDL) receptor, apoE receptor 2, multiple epidermal growth   
factor-like domains 7 (MEGF7), glycoprotein 330 (gp330/megalin/LRP2), LRP1, and LRP1B that 
have been shown to be promiscuous in ligand binding [70]. LRP1-mediated saporin endocytosis in 
human promyelocytic U937 cells was also demonstrated by LRP downregulation, nicely paralleling 
resistance to saporin and to a urokinase–saporin conjugate [33], while displacement of iodinated 
LRP1-receptor associated protein (RAP) with saporin in these cells was also independently 
demonstrated [71]. Cytotoxicity of both saporin and an ATF-saporin chimeric fusion (see below) could Toxins 2010, 2   2708 
 
be competed with large excess of antigen-purified LRP1 polyclonal antibodies in U937 cells [72].  
In addition, LB6 fibroblasts transfected with the human receptor for urokinase were investigated to 
follow the internalization route of a model urokinase–saporin conjugate, demonstrating after cell 
surface binding to the urokinase receptors, again, a clear role for LRP1 in mediating the chimeric 
conjugate internalization [73]. However, when mouse embryonic fibroblasts (MEF-2) derived from 
LRP1 knock-out mice were exposed to saporin, they showed 10-fold less sensitivity to the toxin, as 
compared to MEF1 cells carrying both LRP1 and low-density lipoprotein receptor (LDLR) [64]; this 
possibly indicatES not only a role for LRP1 but most likely for LDLR, as well, in mediating saporin 
internalization in mouse fibroblasts. After being endocytosed saporin and RTA follow different 
intracellular routes: while RTA cytotoxicity can be blocked by the fungal inhibitor Brefeldin A (BFA) 
and can be enhanced by the addition of a C-terminus KDEL, ER-retrieval motif [33,74], neither the 
Golgi disrupting drug BFA nor addition of a KDEL sequence had any significant effect on saporin 
cytotoxicity [64]. To detect a functional role for ERAD in the intoxication path of exogenously applied 
saporin, toxin dose response curves were compared in wild-type and mutant CHO cell lines, exhibiting 
defects in the ERAD pathway affecting a number of ER-translocating toxins including ricin, but no 
differences could be detected, while evidence for escape from endosomal compartment(s) both for 
saporin and for a urokinase-saporin conjugate was provided [75]. The high cytotoxicity towards 
mammalian cells of chimeras containing saporin or other type I RIPs clearly indicates that these toxins 
have the ability to reach the cytosol after being internalized [76]. Thus, although different lines of 
evidence indicate that saporin and other type I RIPs can efficiently cross cellular membranes, the 
site(s) and mechanism of translocation might be quite different from those used by the catalytic 
subunits of type II RIPs. The intoxication pathway followed by TC (which behaves as an invasive 
toxin that targets syncythiotrophoblasts, macrophages, and T-cells) has been recently investigated [77]. 
TC also binds cell surface receptors belonging to the LDL-related receptor family, and its known 
abortifaciens and renotoxic actions are assumed to be caused by LRP1-mediated uptake in 
trophoblasts and by LRP2/megalin-mediated uptake in proximal tubule epithelial cells [78]. In 
agreement with the latter observations, Jurkatt-T cells (which do not express members of the LDL 
receptor family) are essentially resistant to free TC but turned sensitive to the TC-loaded vesicles 
found secreted by at least two target cell lines, JAR and K562 where part of the endocytosed TC was 
found incorporated into “pomegrenade” vesicles, deriving from multivesicular body (MVB) 
membranes, and was then secreted upon fusion of the MVB with the plasma membrane (Figure 4), 
targeting both syngeneic and allogeneic cells (Jurkatt-T cells). Whether other Type I RIPs are also able 
to exploit this exosome-mediated intercellular trafficking route remains to be clarified. Since some 
gelonin chimeric fusions are able to trigger mammalian cell death following an autophagy   
pathway [79–80], it would seem important to verify whether the latter toxin would also be able to 
hijack this novel exosome-mediated pathway. Finally, much work is required to elucidate the 
intracellular pathways followed by the different chimeric fusion toxins, in order to possibly potentiate 
their effects (see below).  Toxins 2010, 2   2709 
 
Figure 4. Schematic representation of the intoxication pathways followed by Ricin (A), 
saporin (B) and trichosanthin (C). (A) Ricin binds to cell surface glycoproteins and after 
endocytosis is transported through endosomes to lysosomes (not indicated) or following 
endosomal sorting steps to the Trans Golgi Network (TGN) [81] and then retrogradely 
transported from the Golgi complex (passing through sulfation compartments) to the ER 
[82], where the A chain retrotranslocates to the cytosol via ERAD pathways: RTA has been 
shown to interact with negatively charged lipid vesicles and with ER membranes, 
undergoing a conformational change making it a better substrate for the ERAD system 
[33,83]. The molecular details of cytosolic entry via an ERAD-specific membrane E3 
ubiquitin ligase have also been revealed showing how RTA may avoid ubiquitylation and 
proteasome degradation [84]. Finally, after escaping degradation RTA may refold in the 
cytosolic compartment also thanks to the presence of host cell chaperones [85].   
(B) Saporin binding to cell surface is at least in part mediated by low-density lipoprotein 
receptor-related protein (LRP) and after being endocytosed, the toxin reaches the   
endo-lysosomal compartment from where it is delivered to the cytosol following as yet 
unidentified pathway(s). (C) TC binding to cell membranes can also be mediated by LRP 
members and can be delivered to multivesicular body (MVB) and in part incorporated into 
the intraluminal vesicles of this organelle. Fusion of the MVB to the plasma membrane 
allows release of the intraluminal vesicles into the extracellular space where they diffuse 
and can target other syngeneic or allogeneic cells through unknown mechanism(s). 
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The oxidizing potential of endosomes and lysosomes has been recently investigated in Prostate 
carcinoma cells (PC3) to check if the latter would limit the intracellular cleavage of disulfide-based 
antibody-drug conjugates, by a group in Genentech (Roche): Herceptin, approved by the Food and 
Drug Administration (FDA) in 1997 as a monoclonal anticancer therapeutic, was derivatized and 
conjugated via a disulfide sensitive SSP linker to a fluorescent rhodamine red dye. The latter has a 
quenched emission in a dimerized form and would emit only in a reduced monomeric form. Using a 
Green Fluorescent Protein (GFP) redox sensitive variant, roGFP1, which they appended as a tracer tag 
to various markers of organelles, such as Lamp2a for lysosomes or Calnexin for the ER or to   
the Transferrin receptor for labeling recycling endosomes, they evaluated that among internal   
membranes/organelles only the mitochondrial matrix showed a net reducing potential, questioning the 
use of reducible disulfides in the immunoconjugate design (see below, Figure 5) [86]. However, for 
certain ricin immunoconjugates it was suggested that not only the ricin holotoxin, but also the latter 
would be most likely reduced in the ER by Protein Disulfide Isomerase (PDI) coupled to a thioredoxin 
reductase activity [87]. 
Figure 5. From chemically-conjugated immunotoxins to recombinant fusions. Schematic 
representation of a classical immunotoxin (IT) in which a monoclonal antibody is joined 
via a disulfide bond to a toxin domain (A) and recombinant fusions between sequences 
coding for (B) ligands (such as growth factor domains, hormones, autocrine factors) or (C) 
antibody fragments (single-chain antibodies, Fab fragments or disulfide-stabilized Fv) link 
to the toxic moieties via different Linker peptides. 
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4. Historical Uses of Plant RIPs  
For many years, RIPs have found practical applications in different fields, such as in agriculture and 
in medicine. In agriculture, the effect of RIPs on plant viruses—the first to be known, led—as 
described above, to transformation of plants with RIP genes, successfully improving their resistance to 
viral infections [3], despite high-level expression of PAP being harmful to transgenic tobacco [9]. The 
antiviral activity against animal viruses has led to numerous studies on the effect of RIPs, especially 
concerning PAP [88] and TC [89], in HIV-infected cells, hoping for their possible use as an adjuvant in Toxins 2010, 2   2711 
 
AIDS therapy. Although the replication of HIV could be inhibited by several RIPs, the few clinical 
trials gave disappointing results, revealing heavy side effects [90].  
In old traditional Chinese medicine, extracts of the roots of the Cucurbitacea Trichosanthes kirilowii 
Maxim. have been extensively used to induced abortion, an effect due to the RIP TC [91], which is 
highly toxic to trophoblast cells [78,92]. 
Several type II RIPs are potential biohazards, and from time to time there have been reports of 
accidents due to ingestion of toxin-containing seeds or roots, causing severe intoxications which could 
not be effectively treated. Furthermore, ricin has long been considered as a possible weapon for 
warfare and terrorism attacks because of its high systemic cytotoxicity, ease of production and its 
prevalence: for these reasons ricin has been classified as a level B biothreat by the Centers for Disease 
Control [93]. The aim of several studies has been to detect and quantify ricin by highly sensitive 
methods, able to give rapid results if the diffusion of the toxin were suspected [94,95]. Moreover, to 
provide an immune protection against ricin, an intensive search for neutralizing antibodies has been 
performed [96]. Recently, a recombinant vaccine (RiVax) has been developed and found to be safe and 
highly immunogenic in mice, rabbits and humans [97,98]. 
Besides those reported above, we find that the most promising applications of RIPs in experimental 
medicine regard their use as targeted chimeric molecules chemically conjugated or especially as 
recombinantly expressed genetic fusions to different ligands, such as growth factors or antibody 
fragments, capable to deliver them to cells to be selectively eliminated (Figure 5).  
5. Immunotoxins and Targeted Chimeric Toxins 
5.1. Overview 
Despite progress in proteomics and bioinformatics approaches to characterize cell-surface antigens 
and receptors on tumor cells, it still remains difficult to identify novel tumor markers to generate 
cancer vaccines or monoclonal antibody therapeutics. A few targeted monoclonal antibodies have been 
approved by FDA to date for immunotherapy of malignant diseases with an average success rate   
of 30% [99]. To increase the toxin killing potential investigators made use of available target specific 
monoclonal antibodies which were derivatized to include a SS bond in order to allow chemical 
conjugation to the protein toxin of choice, leading to the construction of the chemically constructed 
immunoconjugates (Figure 5), also-called “Immunotoxins” (IT) (which will be the main subject of one 
of the next “Toxins” issues for readers interested in a deeper understanding of this vast and complex 
topic). For a more comprehensive view on ITs prepared using RIPs please refer to [100]. From these 
first chemically constructed ITs, research has naturally led from the pioneering work of Hudson and 
collaborators [101,102] to the most recent advances in design of recombinant single chain variable 
fragment (scFv) antibodies (which retain the immunoglobulin-derived domains that recognize 
antigenic epitopes) to scFv toxin fusions, the modern ITs [103] and to development of fully 
recombinant ligand toxins (Figure 5). Ontak or “Denileukin diftitox” is the first chimeric toxin which 
includes diphtheria toxin toxic domain and Interleukin-2, to be approved and commercially available 
for treating patients affected by recurrent T-cell lymphomas expressing CD25/IL-2 receptor [103–105].  Toxins 2010, 2   2712 
 
Among critical factors that determine the successful delivery of an IT or cytotoxic chimera, in terms 
of specificity and cytotoxicity, is the antigen targeted on the tumoral cell surface. Ideally, a target 
should be almost exclusively found expressed on the tumor cells and should be capable of mediating 
internalization, after specific binding of the IT at the cell surface, in order to facilitate the access of the 
toxin moiety to the cytosol. However, genuine tumor-specific antigens are rare. Hence, an useful 
alternative is targeting antigens or receptors that are significantly over-expressed on tumor cells, so 
that peripheral toxicity is limited.  
The well documented immunogenicity of antibody-toxin constructs (see below) is due to the large 
size of the monoclonal IgG molecules, their mouse origin and the long circulation time, possibly 
enhancing antigenic properties of the toxin domains, as well. To circumvent these problems a number of 
molecular engineering approaches can be envisaged, in order to reshape the conventional antibody-toxin 
conjugate: antigenicity of the antibody moiety can be limited by humanizing the antibody and 
choosing smaller antibody formats containing only the variable domains, recognizing the antigenic 
epitopes of the heavy and light immunoglobulin VH and VL, linked together through a small peptide 
linker. Developing single chain antibodies adds flexibility in terms of the design of the engineered 
molecules (VH-VL or VL-VH orientation, type and length of the linker peptides, tandem sequence to 
allow for expression of dimeric (bivalent) versus monomeric molecules, bispecific constructs targeting 
more than one marker antigen, simultaneously. Improved tumor penetration is also expected due to the 
reduction in size. In fact, major concerns have been raised regarding plant toxins [105], particularly for 
their use in oncologic patients with solid tumor masses which may require prolonged treatment 
regimens [105]. In fact, it must be underscored that IT approaches would seem to be better suited for 
fighting hematologic malignancies, especially because of the different physiological/biologic barriers 
for local toxin concentration that solid tumors present against IT penetration and because patients with 
such malignancies are often immuno compromised [103–105]. Indeed, treatment of solid tumors may 
present potential bottlenecks due to the high interstitial fluid pressure gradient within the tumor 
generated by the hastily formed vascular architecture that limits the diffusion of large macromolecules, 
such as full-length antibodies, in the tumoral mass. This problem is also in part counteracted by using 
the smaller antibody formats, such as scFvs, for which several pharmacokinetics and biodistribution 
studies have been carried out [106–108]. Moreover, as stated above, single-chain antibodies may offer 
the possibility to reduce immunogenicity because of their smaller size, the absence of an Fc portion 
and, in particular, their more rapid clearance kinetics from the blood circulation. 
5.2. RIP-Based Immunotoxins  
Deglycosylated native ricin A was the first RIP to be conjugated to RFB4, an anti-CD22 
monoclonal antibody, and examined in two phase I trials, one performed in 15 patients with refractory 
B-cell lymphoma where partial responses were achieved in 38% of evaluable patients, however, with 
three patients who made antibody against A chain, and a fourth who made antibody against both A 
chain and mouse immunoglobulin [109]. Vascular leak syndrome (VLS, see below) was dose-limiting 
for this RFB4 IT when administered to 26 patients whose B-cell lymphoma had relapsed after 
conventional therapies [110]. As compared to ricin-based ITs, saporin has been exploited relatively 
little as the toxin of choice for clinical uses, so far [100,109,111]. A small clinical study with an  Toxins 2010, 2   2713 
 
anti-CD30 monoclonal conjugated to the seed extracted saporin (BERH2-SAP) and administered to 
patients with advanced Hodgkin’s lymphoma, proved very encouraging [111]. Out of four patients 
treated with escalating doses of BERH2-SAP, one had a complete response and two had partial 
responses with a 75% to 25% reduction in the tumor mass. Notably, no serious drug-related toxicities 
were reported in this study; however, antibodies against both domains were raised in the treated 
patients. ITs based on saporin have been used by Flavell and coworkers for their clinical trials in adult 
and pediatric patients with hematological malignancies, their pre-clinical studies showed that an   
anti-CD19 IT BU12-saporin and an anti-CD38 IT OKT10-saporin [109] displayed selective antitumor 
activity both in vitro and in vivo against malignant target hematological cells. In addition, by using 
combinations of ITs targeting more than one cell surface marker antigen simultaneously, a significant 
synergistic therapeutic performance could be obtained in Severe Combined Immunodeficiency (SCID) 
mice model of leukemia and lymphoma [112]. An anti-CD19 saporin IT has previously also been 
evaluated in two separate Phase I studies in adults with B-cell follicular lymphoma and in children 
with relapsed and refractory B-lineage acute lymphoblastic leukemia (ALL). No major toxicity was 
encountered and none of the patients developed human anti-mouse antibody responses [109]. 
However, the intrinsic heterogeneity of all such chemical conjugates would have precluded their 
successful development into potential therapeutic molecules [104,109]. Recombinant approaches are 
now pursued also by Leukemiabuster charity, as well, to open the way to a new class of saporin-based 
therapeutic molecules against hematologic malignancies [54]. 
Some ITs have been produced but only using RIP domains expressed in bacterial hosts or,   
vice versa, by conjugating recombinantly expressed targeting domains to the native protein toxins. 
Among them, a conjugate of recombinant RTA with a monoclonal against the Transferrin (Tn)   
receptor [113], directed towards brain neoplasia and administered intraventricularly to patients, and a 
conjugate of anti-CD33 humanized monoclonal antibody with recombinant gelonin, endowed with 
antileukemic activity [114]. Recently, an antileukemia IT has been obtained with a single chain 
antibody expressed in the yeast Pichia pastoris derived from an anti-CD7 monoclonal antibody which 
was, nevertheless, chemically conjugated to RTA [115]. In addition, some other recombinant-based 
chimeras have been tested such as one between the N-terminus of the viral glycoprotein of vesicular 
stomatitis virus fused to RTA that was produced and then, nevertheless, chemically conjugated to 
human Tn and that showed a 15-fold increase in cytotoxic activity as compared to the parental   
IT [116]. A promising approach in vivo for therapy of transplanted organ rejection and graft-versus-host 
disease (GVDH) is to efficiently kill alloreactive cells by selective depletion of T cells, targeting 
Cytotoxic T-lymphocyte Antigen-4 (CTLA4/CD152) [117]. CTL4 is highly expressed on several 
hematologic malignancies and on activated T cells, responsible for transplant rejection and 
autoimmune diseases. Two phage display selected single-chain human antibodies, scFv83 and scFv40, 
recognizing two different epitopes on CD152 dimers, were chemically conjugated via a SS bond to 
seed extracted saporin and their efficacy in vivo in an acute mouse rejection model investigated. The 
inhibitory in vitro activities measured in reticulocyte translation after IT reduction were found to be 
similar for both IT, only about 3–5 fold less potent than saporin alone. CTLA4 surface expression is 
restricted to T cells and upon T cell activation dimers become rapidly internalized: cell killing 
activities were assayed against activated T cells and B lymphoblastoid cells, as allogeneic targets.  
The 83-saporin concentration causing 50% apoptotic death (AC50) of stimulated T lymphocytes was Toxins 2010, 2   2714 
 
in the picomolar range. Since 83-saporin showed a stronger reactivity, the latter IT was chosen for in 
vivo administration to a mouse model carrying an implanted allogeneic endothelioma displaying   
T lymphoid cell inflammatory infiltrates. 4 µg 83-saporin IT was injected in a group of four mice at  
days 0, 1 and 2: while a marked infiltration was detected in tumors of control PBS-injected mice, 
scarce to moderate infiltration was observed in treated mice, with—most importantly—no signs of 
acute organ toxicity post-mortem [117]. Recently, an internalizing human anti ALCAM-scFv was also 
selected by phage display on whole tumor cells and then conjugated to seed saporin in a similar way, 
showing specific killing activity against target tumor breast cells [118]. These data demonstrated that 
the phage display techniques can be used to select scFv variants with an improved efficacy when fused 
to seed saporin, reducing the toxic side effects normally associated with this approach. 
5.3. RIPs and Recombinant Fusions Expressed in Bacteria: Targets and Molecular Design  
The use of plant-extracted RIPs as such or incorporated into immunoconjugates could be limited 
during preclinical and clinical testing by the presence of heterogeneous preparations with several 
immunologically distinct toxin isoforms which may also vary significantly in their catalytic   
activities [33], thus recombinant expression of single isoforms is advisable. The Escherichia coli 
bacterial system was the first one to be explored. The recombinant protein may be recovered as soluble 
material, or may accumulate inside inclusion bodies [33,109]. In this latter case, inclusion bodies must 
be isolated, purified and solubilized. The proteins are then extracted by denaturation and refolded in 
the presence of an appropriate redox buffer, while endotoxin contaminations may be a common 
problem of bacterial expression systems [119]. 
While RTA was successfully produced in bacterial cells [120] since it is not toxic towards 
prokaryotic ribosomes, in constrast, dianthin 32, which is highly similar to seed saporin, was found to 
be active on E. coli ribosomes and 500-times more active on yeast ribosomes, specifically   
depurinating 23S rRNA at a site which is equivalent to A4324 in rat 28S rRNA [121]. Therefore, 
saporin and other type I RIPs, such as PAP [122] and Mirabilis antiviral protein [123] and more 
recently luffin [124], being active also on E. coli ribosomes [121], required a tight regulated 
host/vector inducible system, such as the one used for the expression of dianthin and mature saporin 
isoforms [33,34]. Plasmid pET vectors used for these expressions contain the T7 promoter, and are 
used to transform E. coli strains (i.e., BL21(λDE3)) containing the T7 RNA polymerase gene in   
the bacterial chromosome and placed under the control of lacUV5 promoter. Addition of   
isopropyl-D-thiogalactopyranoside (IPTG) induces expression of T7 RNA polymerase and hence of 
the recombinant toxin. A tighter control of T7 RNA polymerase expression is obtained using   
plysS-containing E. coli strains (i.e. BL21(λDE3)plysS, AD494(λDE3)plysS), which constitutively 
produce low amounts of T7 lysozime—a natural inhibitor of T7 RNA polymerase [125]—thus, 
avoiding any leaky accumulation of active RNA polymerase and, consequently, of the toxin. Indeed, 
by using this host, no saporin polypeptides were detected in the absence of the inducer, but a few 
milligrams of soluble protein per liter could be purified from bacterial lysates, part of the protein being 
accumulated as inclusion bodies [34]. Recently, a recombinant saporin bearing a C-terminal VSAV 
tetrapeptide (SapVSAV), recognized by a specific PDZ domain, has been expressed in the BL21(DE3) 
host. The yield of saporin in the soluble fraction was greatly enhanced when the corresponding PDZ Toxins 2010, 2   2715 
 
domain was co-expressed. Surprisingly, the increase in saporin production was not due to protection 
from bacterial auto-intoxication but most likely from a stabilization effect of the PDZ domain on the 
toxin during biosynthesis. Interestingly, this recombinant saporin was not toxic to free ribosomes 
although fully active to human cancer cells [126]. Concerning Type I plant RIPs, only a few 
recombinant fusions have been produced until now. 
An intriguing example concerning RTA fusions is a hybrid toxin expressed in E. coli, PE-RTA, in 
which the ADP-ribosylation domain of Pseudomonas Endotoxin A was replaced by the N-glycosidase 
domain of RTA. The latter chimera has been used essentially to investigate the intracellular pathway(s) 
of these toxins, demonstrating that cytotoxicity of PE-RTA was approximately two orders of 
magnitude less than either native PE or the ricin holotoxin, but that the addition of the KDEL 
tetrapeptide to its C-terminus (producing PE-RTA-Lys-Asp-Glu-Leu) increased cytotoxicity to the 
same level of the native toxins [127].  
PAP has gained considerable interest for its use as either a ribosome inhibitory anticancer agent, or 
as a broad-spectrum antiviral agent (see above) and some efforts to obtain active PAP-based fusion 
proteins have been made. A recombinant chimera between PAP and Interleukin IL-2 was expressed in 
E. coli and the inclusion body fraction, mainly containing the recombinant protein, was isolated and a 
denaturation/renaturation process established to prepare the soluble fusion protein [128]. The fusion 
protein was as active as free PAP in inhibiting reticulocyte cell-free translation system while only the 
chimeric protein inhibited translation of the CTLL-2 target cell line which expresses IL-2   
receptors [129]. On the contrary, in a more recent work, either mature PAP or the full-length precursor 
sequence containing both the signal peptide and the C-terminal propeptide were fused to the 
gonadotropin-releasing hormone (GnRH) to specifically target cells bearing the GnRH receptor, 
including several cancer cell types, and expressed in E. coli [129]. Binding and cytotoxicity of these 
two hormonotoxins were compared to a chemically-conjugated GnRH-PAP: surprisingly, although the 
conjugate bound specifically to and caused cell death via apoptosis in cells exposing the target 
receptors, no binding nor cytotoxicity was observed when the same cells were treated with the latter 
two recombinant fusions, possibly because both ends of the GnRH moiety are required for receptor 
binding, while only the N-terminus was left free in the recombinant chimeras [129].  
Basic fibroblast growth factor (bFGF)-saporin was the first recombinant fusion chimera based on 
saporin expressed in E. coli shown to be highly selective and cytotoxic towards FGF2   
receptor-expressing cells [130]. Moreover, recombinant basic FGF-saporin fusion also showed 
significant anti-proliferation activity when tested in animal models of human ovarian teratocarcinoma 
or melanomas in a combination therapy [131,132]. Another example of a fully recombinant saporin 
fusion is represented by an EGF receptor-targeted fusion between a heparin-binding epidermal   
growth factor (HEGF) and saporin, showing selective cytotoxic activity towards human breast 
carcinoma cells [133].  
One of the fusions targeting the receptor of urokinase (uPAR) is ATF-SAP, which consists of the  
N-terminal portion (ATF) of the receptor binding domain of human urokinase (huPA) fused to a seed 
saporin isoform which has shown the potential to specifically kill tumor cells over-expressing huPA 
receptors [72]. uPAR focuses pro-uPA at the cell surface, increasing its rate of conversion into active 
uPA, a serine protease which converts plasminogen into active plasmin, leading to cell matrix 
degradation [134,135]. Human uPAR is over-expressed at the leading edge in several metastatic tumor Toxins 2010, 2   2716 
 
cells, mediating tumor cell dissemination [136–140], and this is the reason why this receptor represents 
an important drug target [134–140]. An intriguing feature was that, in contrast with uPA, ATF-SAP did 
not require plasminogen activator inhibitors (PAI) to be internalized, indicating that saporin has the 
ability to trigger internalization of uPAR-bound ligands through LRP endocytotic receptors [70–71]. 
However, ATF-SAP expression into the bacterial host was problematic due to misfolding problems [72], 
thus hampering further pre-clinical and clinical investigations. Pseudomonas exotoxin A and diphtheria 
toxin are the most commonly used bacterial toxins in IT constructs [141] because they also inactivate 
protein synthesis by ADP ribosylation of elongation factor 2, thereby leading to cell death. DTAT is a 
diphtheria toxin fusion similar to ATF-saporin, produced by fusing a toxic fragment of the diphtheria 
toxin (DT) to ATF [142–144]. A bispecific IT, DTAT13, was then further engineered by adding the 
mature peptide of human IL-13 in between the ATF portion and a diphtheria toxin toxic moiety 
[145,146]. DTAT and DTAT13 could effectively kill tumoral cells in glioblastoma multiforme and 
acute myelogenous leukemia [146]. Efficacy of DTAT13 was significantly better in inhibiting a range 
of xenograft tumors and showed that DTAT13 was 160- and 8-fold less toxic compared to the parental 
fusion ITs, DTAT and DTIL13 [146]. Intracranial biodistribution studies revealed that DTAT13 was 
able to cross to the contralateral hemisphere, unlike DTIL13 but similar to DTAT. These studies 
showed that DTAT13 has properties encompassing those of both DTIL13 and DTAT and would 
warrant further consideration for clinical development [146]. However, in spite of the great promises 
shown by bacterial toxin-based chimeric proteins, their use also posed several obstacles that have 
limited their wider clinical application, since the toxin part of these fusion proteins may elicit a high 
degree of humoral response in humans [147]. Another bispecific DT recombinant IT targeting both 
CD19 B cell marker of leukemia/lymphoma and CD22 marker on B cell leukemias (which had a much 
better antitumor activity than a mixture of the two monospecific ITs), recently in Phase I clinical trials, 
encountered the same immunogenicity-related problems encountered with Ontak/denileukin [80,94]. 
Besides, in developed countries where people are immunized against diphtheria, serum will have 
circulating antibodies against diphtheria toxin [148].  
The development of recombinant ITs has markedly affected the fields of targeted therapeutics, 
allowing different molecular design approaches, in order to engineer molecules with improved in vitro 
and in vivo stability and better functionality [149,150].  
The Type I RIP gelonin is one of the most promising plant toxins used to construct several 
recombinant ITs expressed in bacteria. One anti melanoma IT was obtained by fusing the N-terminus 
of gelonin to a single-chain antibody directed against gp240, the high molecular weight glycoprotein 
which is specifically over-expressed in melanoma cells [79]. This IT was characterized by having a VL 
domain connected to the VH domain via an 18-amino acid flexible linker (218 linker: 
GSTSGSGKPGSGEGSTKG), enhancing proteolytic stability and causing reduced aggregation of 
scFvs when expressed in bacterial systems [151]. A G4S peptide linker [79,80] was used to connect the 
single chain antibody to the toxin domain, carrying a hexahistidine-tag for nickel affinity purification. 
IT was expressed in the thioredoxin-reductase minus E. coli AD494(DE3) pLysS strain, with yields 
around 0.7 mg per liter down to 0.2 mg of purified material, possibly the purification was too 
inefficient purification due to hindering of the hexahistidine-tag. The protein synthesis inhibitory 
activity of the fused gelonin was virtually identical to the non-fused toxin (around 100 pM), suggesting 
no significant steric hindrance of the gelonin active-site cleft is given by the single chain antibody Toxins 2010, 2   2717 
 
domain. This would seem to contrast with studies using ricin A-chain-based IT, which required release 
from the protein partner to recover full biological activity [120,152]. The IT showed an IC50 value  
of 8 nM (versus 2000 nM of free gelonin in an in vitro cytotoxic assay on antigen-positive A-375 
human melanoma cells), identical to the parental gelonin chemical immunoconjugate. Surprisingly, 
cytotoxicity was not mediated by apoptotic mechanisms. In addition, studies conducted on   
tumor-bearing nude mice showed that the tissue: blood ratio was highest for tumors with respect to 
other tissues at 72 h after administration of the IT, due to its relative rapid clearance from the   
circulation [77]. A more recent study provides a comprehensive examination of the effects of IT design 
on the ability of different constructs to target cells expressing the Her2/neu oncogene product,   
a 185 kDa transmembrane glycoprotein kinase, which is highly expressed in breast and ovary   
cancers [153]. By constructing ITs containing either a human single-chain antibody (scFv) C6.5 or the 
murine scFv e23 fused to recombinant gelonin (rGel) molecule, using the flexible G4S linker (L), the 
fusion construct C6.5-L-rGel was directly compared to e23-L-rGel and specific cytotoxic effects 
evaluated against Her2/neu-positive and Her2/neu-negative tumor cells. Both constructs retained the 
specificity of the parental scFv antibody, as well as the biological activity of rGel toxin and displayed 
similar cytotoxicities against different carcinoma cells. In addition, two different cleavable linkers Fpe 
linker: TRHRQPRGWEQL (a sequence deriving from Pseudomonas exotoxin A) and Ftd linker: 
AGNRVRRSVG (a sequence deriving from diphtheria toxin) containing sites proteolytically cleaved 
by furin, a protease found in recycling endosomes to Golgi, were also examined to check for a more 
efficient intracellular release of gelonin. The introduction of the cleavable linkers into the molecules 
resulted in a dissimilar sensitivity to protease cleavage, as compared to the first two constructs 
containing the L linker alone, although they all exhibited a very similar intracellular rGel release, 
cytotoxic kinetics, and induction of autophagic cell death. However, constructs carrying the L linker 
showed higher stability in vitro as well as in xenograft mouse studies where they were more efficient 
in tumor inhibition than the constructs containing furin sensitive linkers, thanks also to their higher 
stability in vivo [153]. A further gelonin-based chimera was generated by fusing the toxin to a B 
lymphocyte stimulator (BLyS), a member of the tumor necrosis factor superfamily of cytokines that 
selectively binds B cells and is known to promote B cell proliferation, activation and differentiation. 
BlyS receptors are over-expressed in a broad range of tumors, including multiple myelomas and 
several lymphomas, such as large B cell lymphoma, non-Hodgkin’s lymphoma and Burkitt’s 
lymphoma. The fusion toxin rGel/BLyS containing gelonin at the N-terminus, followed by the G4S 
linker peptide tethered to BLyS, was expressed in the bacterial system and was found to be highly 
cytotoxic against lymphoma cell lines, being rapidly internalized into target cells [154]. Differently 
from the gelonin-based chimeras described above, further studies provided strong evidence that its  
in vitro and in vivo cytotoxic effects could be mediated by canonical apoptotic mechanisms [155–157].  
Unlike antiangiogenic drugs that inhibit formation of new blood vessels, vascular targeting agents 
(VTA) may occlude pre-existing blood vessels of tumors to cause tumor cell death through ischemia 
and extensive hemorrhagic necrosis. Among ligand-based VTAs, we may find vascular endothelial 
growth factor fusions (VEGF) to the plant toxin gelonin, ITs (monoclonal antibodies to endoglin 
conjugated to ricin A), antibodies linked to cytokines, liposomally encapsulated drugs and gene 
therapy approaches [158]. (VEGF)-gelonin is a highly selective carrier, targeting tumor endothelial 
cells, which showed promising applications. (VEGF)-gelonin fusions are able to inhibit tumor growth Toxins 2010, 2   2718 
 
and metastasis dissemination, and recently, by a fed-batch cultivation method the investigators could 
achieve high cell densities, comparable to those obtained with the methylotrophic yeast strains (of 
about 40 OD/mL) with an overall production of a biologically active histidine-tagged VEGF-gelonin 
fusion in AD494 pLysS of 42.5 mg/L (compared to 1.6 mg/L produced using conventional flask 
cultivation methods) [159]. An Abrin-VEGF121 fusion protein was also recently obtained in E. coli in 
inclusion bodies, yielding both monomeric and dimeric forms [160]. Basic FGF, VEGF and EGF are 
relatively short protein domains which may not require special folding assistance and which do not 
need N-or O-glycosylation for being biologically active, and thereby, good yields may be obtained 
when expressed as fusion toxins in bacterial hosts. However, some fusions were quite difficult to 
produce in this system, such as the one between ATF and saporin due to misfolding and degradation of 
the human targeting domain [72]. 
6. Yeast/Eukaryotic Expression Systems 
Differently from bacterial toxins-based fusion proteins which can be expressed at high yields in the 
bacterial system, only few recombinant fusions containing plant RIPs have been successfully produced 
using the bacterial hosts. Surprisingly, despite RTA could be produced in bacteria at high levels, 
recombinantly expressed fusions to RTA did not seem to be very popular [109]. Thus, development of 
eukaryotic production platforms for safe expression of RIP fusion proteins would be highly desirable, 
since low protein yields, endotoxin contaminations and inefficient folding of eukaryotic secretory 
domains used for targeting, as in the case of the ATF domain [72], represented potential bottlenecks in 
using prokaryotic expression systems.  
Human interleukin-2 was fused to RTA and constructs containing N-terminal IL2 and C-terminal 
RTA, or N-terminal RTA and C-terminal IL2, could be expressed in Xenopus laevis oocytes. The IL2 
and RTA domains were joined by a peptide in which two different proteolytically-sensitive peptide 
sequences were utilized: one that forms the trypsin-sensitive disulfide-bonded loop in DT or a 
synthetic peptide containing factor Xa recognition site. Chimeras not pre-digested with factor Xa   
(but which contained the factor Xa target sequence) were not cytotoxic to CTLL-2 cells. Rather, they 
showed a stimulatory effect due to the IL2 moiety. In contrast, recombinant chimeric toxins containing 
the DT loop sequence were found cytotoxic to CTLL-2 cells [161]. Taken together, these data 
suggested that RTA-containing chimeras required intracellular proteolytic cleavage to allow release of 
the toxin moiety and would suggest that a non toxic precursor was expressed and secreted in the 
oocyte system. Secretory ATF-saporin could be expressed in micromolar amounts using the Xenopus 
oocyte expression system but only if the oocytes were co-injected with neutralizing anti-saporin 
antibodies, indicating that saporin was able to reach the cytosolic compartment, in this case [74]. 
In the last years, the methylotrophic yeast Pichia pastoris has been shown to be a suitable host  
for high-level expression of various heterologous proteins, especially endowed with clinical and   
potential high therapeutic value, expressed either intracellularly or in secreted forms [162]. Indeed,  
Pichia pastoris is a microbial host that recapitulates most of the co- and post-translational 
modifications during protein biogenesis and possesses an ER quality control system allowing only 
secretion competent polypeptide to reach the extracellular medium. This eukaryotic system was 
exploited to successfully express mature PAP, which was expressed as a precursor carrying the Toxins 2010, 2   2719 
 
preproalpha mating factor leader sequence and secreted by the protease-deficient strain SMD1168H 
with average yields of 12 milligrams recombinant PAP (rPAP) per liter of culture supernatant. The 
secreted rPAP showed the same in vitro enzymatic activity and cellular anti-HIV activity of native PAP 
purified from Pokeweed, Phytolacca americana L. [163]. Interestingly, it was found that rPA 
expression was not toxic to the yeast cells, although this RIP should be able to inactivate both 
prokaryotic and eukaryotic ribosomes [9,12,109,121], thus suggesting that a rapid and/or very   
efficient secretion into the culture medium likely prevented rPAP from interacting with the yeast host 
ribosomes [163]. Neville's group pioneered the expression of recombinant IT fusions to DT in   
Pichia pastoris and found GS115 strain particularly tolerant to this bacterial toxin [54,164]. More 
recently, Pichia pastoris was also explored for secretion of saporin and saporin fusion chimeras [54], 
however, in contrast to what was found during PAP expression [163], SMD1168 strain was not able to 
induce this plant RIP. Moreover, independently from the strains used and the construct design, some 
host toxicity was always observed when inducing saporin expression, which was due to RIP activity, 
since the catalytically-inactive KQ saporin mutant (see above) showed no such toxicity when 
expressed under the same conditions. It is worth noting that saporin gene-codon optimization was 
essential to obtain clones expressing high-levels of active saporin in GS115 strain (up to 30 mg/L), 
presumably due to lower detrimental effects on the cell host protein synthesis machinery [54]. 
Although saporin was efficiently secreted, secretion efficiencies were lower when some fusion 
chimeras were expressed, a fraction of the latter being retained in the cell and degraded in the yeast 
vacuole [54]. Notably, secretion efficiency was found to strictly depend on the nature of the targeting 
domain fused to the toxin: while saporin recombinant ITs with different murine or human single-chain 
antibodies were mostly retained and degraded, the secretion efficiency of ATF-saporin chimera was 
comparable to that of saporin, indicating that a good secretory domain may be important to avoid 
misfolding and/or targeting to the vacuolar compartment [54]. Among the saporin recombinant ITs 
investigated, different construct designs were tested and the expression levels of the resulting saporin 
chimeras have been compared. Our results indicate that gene-codon optimization of the targeting 
domain seems also essential to obtain the latter in high yields [165],). In addition, we also used   
the 218 linker [151] between the variable VH and VL domains in the scFv design, finding it was much 
better than the canonical (G4S)3 linker [101,102] also during expression of saporin fusions to scFv in  
Pichia pastoris. However, when we tested the reverse configuration: VL-218L-VH, widely used in 
many toxin-based ITs [79,80], no fusion polypeptide could be induced. The highest secretion yields 
were obtained when the saporin toxin domain was instead placed at the N-terminus of the scFv but in 
this case no cytotoxicity data are yet available, thus, we can not exclude that this particular fusion 
might be non toxic [165]. 
7. Immunogenicity and Non Specific Toxicity Issues 
A major drawback when using murine targeting domains, as well as plant or bacterial toxins as 
therapeutic agents, is represented by their potential immunogenicity after repeated administrations. 
The development of ITs containing humanized antibodies or antibody fragment lacking Fc portions 
may in part resolve these problems by avoiding the induction of human anti-mouse antibodies 
(HAMA) directed to the Fc murine fragments in treated patients [166–168]. Moreover, the presence of Toxins 2010, 2   2720 
 
a bacterial or plant toxin can trigger the formation of neutralizing antibodies, hindering their efficacy. 
In patients with B- or T-cell malignancies, the formation of neutralizing antibodies is less frequent 
because of their immuno-suppressed state; in contrast, in patients with solid tumors, antibody 
responses are frequently detected as early as a few days after the first treatment regimen, preventing 
re-administration of the ITs [169,170]. Many efforts are being made to decrease immunogenicity of the 
toxin moiety; one possibility explored is masking of the therapeutic molecules by use of 
polyethylenglycol (PEG) derivatization techniques [171]. An impressive result was obtained recently 
by Onda and coworkers, who identified the seven major immunogenic B-cell epitopes in a truncated 
form of Pseudomonas aeruginosa exotoxin A (PE38) [172]. A total of eight amino acids containing 
large bulky hydrophilic side chains have been replaced with smaller polar residues within these 
epitopes, resulting in a new toxin endowed with much less immunogenicity than the parental one, 
without any loss of cytotoxic activity also when recombinantly fused to either an anti CD22 variable 
fragment (which was tested both in vitro and in mice model of lymphomas [173]) or used in a bispecific 
anti CD22 and anti CD19 IT construct carrying an ER-retrieval motif (2219KDEL7mut) [80]. In the 
latter case, serum from mice immunized with multiple injections of 2219KDEL7mut had 80% less 
antitoxin antibodies than mice immunized with the non mutated IT [80]. Interestingly, human IT 
treatment induces human antibodies against the same seven immunogenic epitopes identified in the 
mouse sera [172,173], thus confirming that the murine model is an acceptable immunogenicity model 
also for humans. 
Concerning the plant toxins, the C-terminal domain (residues 203–247) of TC, which contains a 
putative antigenic site, was systemically deleted. Residues 1 to 240 was the minimum length of TC found 
to fold into an active conformation and reduced immunogenicity by 3-fold, but lead to a loss of RIP 
activity by about 10-fold [174]. Another Type I RIP, bouganin from the leaf of Bougainvillea spectabilis 
Willd. [175], was mutated to remove most T-cell epitopes, without affecting its biological activity, as 
compared to the wild-type molecule. This patented bouganin variant was genetically fused to an anti 
ephitelial cell adesion molecule (EpCAM) Fab fragment via  a peptide linker containing a furin 
proteolytic site. resulting in the VB6-845 IT for treatment of solid tumors. VB6-845 IT was produced 
in  E. coli by the Canadian company Viventia Biotechnologies Inc. and successfully tested on   
EpCAM-positive human tumor xenograft model in SCID mice [176]. A comprehensive series of 
pharmacology and toxicology studies have been conducted using VB6-845, including a phase I trial in 
patients bearing advanced squamous cell carcinomas of the head and neck. The results of this phase I 
trial showed that VB6-845 could reduce or stabilize tumors in 71% of patients with a maximum 
tolerated dose of 280 mg of IT, administered daily for five days. The IT was well tolerated with the 
only adverse effects being pain due to the intratumoral injections and reversibly elevated liver 
enzymes. These promising results warrant further clinical development of this plant RIP-based   
IT [177,178]. However, effects of the T-epitope removal on in vivo immune recognition are not yet 
being disclosed by the company. 
A further complication observed in IT administration in the past was due to nonspecific binding of 
the toxin domain to vascular endothelial cells, leading to the so-called “vascular leak syndrome” 
(VLS) [179–181], which is characterized by interstitial edema, hypoalbuminemia, weight gain, and in 
most severe cases, pulmonary edema and hypotension. Although the mechanisms underlying this side 
effect are not completely understood, proteins such as RTA and some type I RIPs contain a consensus Toxins 2010, 2   2721 
 
amino acid sequence “X-Asp-Y”, such as found in Interleukin-2, where X could be Leu, Ile, Gly or Val 
and Y could be Val, Leu or Ser, which seems to induce vascular damage to human endothelial cells  
in vitro by binding to integrin receptors [179–181.] Indeed, in the case of RTA, molecular modeling 
suggested that these motifs were partially exposed on the surface of the molecule [179] and a similar 
motif is shared by viral disintegrins, which disrupt the function of integrin receptors [182]. In the 
perspective of eliminating VLS during therapeutical use of ricin-based ITs, Vitetta and coworkers 
produced a series of RTA mutants, and identified the Asn 97 to Ala mutation, in a region flanking the 
VLS-responsible motif in the three-dimensional structure, as displaying significant less VLS in   
mice [183]. Mutated RTA showing significantly less VLS in mice was also conjugated as an antiCD22 
RFB4 IT and the latter could be injected in a five-fold higher concentration, as compared to the 
parental RFB4 IT [183]. Finally, connected to other unexpected toxicity issues, it is worth mentioning 
that a Phase I study with Combotox, a mixture of anti-CD19 and anti-CD22 RTA-based Its, led 
unfortunately to two drug-related deaths following treatment, due to problems with undetected protein 
aggregation [184]. This highlighted potential unforeseen serious problems with biological therapeutics 
such as IT preparations and indicates that every precaution must be taken to ensure the stability of 
these therapeutic molecules [109]. 
8. Complementary Approaches 
8.1. Proof-of-Concept IT Potential Evaluation with Streptavidin-Saporin  
Among potentially interesting complementary approaches, especially as a proof-of-concept before 
developing and producing a fully recombinant IT, is the use of Streptavidin-saporin to prepare 
conjugates with biotinylated targeted monoclonal antibodies, as proposed by Advance Targeting 
Systems, a company which also previously developed secondary antibodies conjugated to saporin as a 
means to identify the better internalizing target monoclonal antibodies [109]. This approach has been 
successfully used recently with a humanized monoclonal antibody to the prostate specific membrane 
antigen (PSMA), in order to evaluate IT antitumor activity against prostate carcinoma cell lines and  
in vivo as well. Cell surface binding was equivalent to the non-conjugated parental antibody and 
internalization took place specifically in PSMA positive cells but not in PC3 negative control cells. 
The IC50 varied from 0.1 nM to 100 nM depending on the cell line tested while the LNCap model cell 
line was the most sensitive with 60% of the treated cells undergoing apoptosis after 72 h. In a 
xenograft mouse model of LNCap cells, the IT showed potent in vivo anti-cancer activity [185]. 
Retuximab-saporin, an IT targeting human epidermal growth factor receptor (EGFR)-expressing cells, 
was obtained using the chimeric murine-human IgG1 monoclonal antibody Cetuximab (also termed 
C225 or “Erbitux”) bound via the biotin-streptavidin linkage to saporin. Photochemical internalization 
was also used in the latter case to enhance the cytotoxicity of the IT, by favoring its release from the 
endo-lysosomal compartments [186].  
8.2. IT Potentiation Approaches  
Saponins are low triterpenoid compounds mainly produced by plants, including S. officinalis. They 
affect plasma membrane permeability of living cells or artificial membranes by interacting with Toxins 2010, 2   2722 
 
cholesterol and have been shown to greatly enhance saporin cytotoxicity towards several different cell 
lines [187–190]. It was demonstrated that cytotoxicity can be retained together with target specificity 
of a chimeric toxin, thus allowing the broadening of the therapeutic window with a simultaneous dose 
lowering. This saponin-mediated enhanced cytotoxicity was affected by drugs interfering with 
clathrin-mediated endocytosis, while inhibitors of caveolae-mediated endocytosis showed no   
effect and, furthermore drugs known to interfere with endo-lysosomal trafficking could also block  
saponin-mediated effects [33]. Indeed, recent data would suggest saponins treatment may be favoring 
endosomal escape of saporin [188]. A saporin fusion to epidermal growth factor via a cleavable adapter 
was constructed to evaluate its efficacy in inhibiting tumor growth and reduce side effects in vivo. In 
fact, a lethal dose for BALB/c mice was three-times less for the adapter-containing toxin (SA2E) than 
for the adapter-free construct (SE) [119]. Furthermore, SE only reduced the average weight of induced 
tumors by 33% whereas SA2E-treated mice exhibited a 71% reduction showing an almost complete 
suppression in 60% of the cases. Additionally, combined application of saponins increased cytotoxicity 
of SA2E on murine TSA tumor cells transfected with human EGFR by almost 20,000-fold using non 
permeabilizing concentrations of saponins [189]. Cervical cancers are the second most common 
cancers in women and since EGFR is found over-expressed in almost 90% of cervical tumors, targeting 
these receptors seems a promising approach: a combination of EGF-saporin SE fusion toxin with 
saponins resulted in a drastic enhancement of cytotoxicity ranging from 9,000-fold to 2,500,000-fold, 
again depending on the cell lines analyzed. The cytotoxicity of the fusion toxin was clearly target 
receptor specific because free EGF could effectively block this effect and, moreover, for all the 
cervical carcinoma cell lines tested, a clear correlation between EGFR expression and sensitivity to the 
SE fusion toxin could be observed [190]. Lipopolyamine and DMSO treatments have also been shown 
to significantly potentiate saporin and a urokinase-saporin conjugate [75]. Other such non toxic 
compounds/enhancers able to synergize IT administration would be welcome, such as the promising 
exponentially growing research into nano delivery particles whose size, shape, density and surface 
chemistry may dominate convective transport in the bloodstream, favor selective cellular uptake, as 
well as sub-cellular trafficking and localization, allowing greater efficacy and less side effects [191].  
8.3. Non Viral Gene Delivery Approaches  
Hoganson and coworkers [192] have used basic-FGF mediated targeting of FGF-2 receptor-bearing 
cells with either a DNA encoding cytosolic saporin or, for comparison, with one encoding the 
cytotoxic gene of herpes simplex virus thymidine kinase which is able to efficiently kill target cells by 
activating the ganciclovir prodrug and is so far the most widely used suicide gene in cancer gene 
therapy approaches. When the investigators compared FGF2-mediated delivery of a mammalian 
codon-optimized saporin gene to thymidine kinase DNA (followed by ganciclovir treatment) in tumor 
target cells, they resulted in a 60% and 75% decrease in cell numbers, respectively [192]. The driving 
idea is targeting tumor cells in vivo by means of synthetic carriers such as polycations in which 
selected binding peptides have been incorporated in order to trigger internalization of the DNA 
complexes within target tumor cells. This system has been patented [193] by Selective Genetics and 
covers the possibility to use several DNAs, including the Type I RIPs gelonin and saporin, and   
could be well included in the new frontiers of promising exponentially growing nanomedicine   Toxins 2010, 2   2723 
 
approaches [191,194–196]. In vivo delivery of genes encoding saporin or other Type I RIPs, might 
therefore also have great therapeutic potential for solid tumor treatments, as well. Indeed, we 
demonstrated that the intra-tumoral delivery of as low as 50 ng of a plasmid DNA encoding cytosolic 
saporin in an animal model, bearing an aggressive tumor such as B16 melanoma, could significantly 
retard tumor growth [53] and this was clearly due to the effects of a catalytically active toxin. A book 
dedicated to cancer gene therapy approaches includes also a chapter detailing preparation of   
cost-effective non-viral vectors loaded with the plant toxin gene for anticancer suicide gene   
therapy [196]. An intriguing observation we made was the presence of necrotic lesions at the injection 
site of B16 melanomas when using the native wild type saporin DNA but not a KQ inactive   
mutant [53], suggesting this might be due to secondary effects mediated by active saporin [53,196], 
which could partly be due to bystander effects by T-Killer cells. Interestingly, a similar observation 
was made when using a Plasminogen activator inhibitor-Saporin conjugate (which has been patented 
by Jankun and Hart as a method to deliver medicaments to cancer cells [197]). The conjugate, which 
was evaluated in a fibrosarcoma model in SCID mice and injected intratumorally, showing an effective 
antitumor response on mice with no systemic toxicity, revealed the presence of necrotic foci at the 
tumor site following administration. These intriguing observations deserve further investigations and 
these straightforward, easy and cost-effective cancer gene therapy approaches should be investigated 
for other Type I RIPs. These are potentially useful not only for accessible tumors but also after surgical 
removal of primary tumors for minimal residue killing of potentially harmful cells.  
9. Conclusions and Perspectives 
Out of the 2485 entries retrieved in the Public NIH medical library database when entering 
“ribosome-inactivating protein” as a key word, half included ricin A chain or saporin, indicating the 
broad scientific interest these two plant RIPs have gained over the past years. While Ricin A chain has 
been explored more in targeted immunotherapy approaches for treating oncologic patients, 
highlighting some critical problems such as VLS that could be in part overcome [179–183], the worse 
problems faced were aggregation-prone preparations of RTA-based ITs [184]. In the case of saporin 
and other Type-I RIPs, less has been done and there are still several options to be pursued to optimize 
their therapeutic use (which could also be of interest to pharma companies). For instance, an Amgen 
patent covering single chain antibodies directed against deletion mutants of EGFR vIII and their 
therapeutic uses, also extended the patent to conjugation of the latter scFvs to several toxins selected 
from a group of different ones that also includes the plant RIP saporin [198].  
Better design of fusion molecules, depletion of immunodominant epitopes, removal of sequences 
suspected of triggering VLS might give us the opportunity to fully exploit Type I plant toxins. Finally, 
the use of eukaryotic hosts for the large scale expression of the chimeric molecules will help to avoid 
misfolding and aggregation problems. Last but not least, the study of intracellular routes used by the 
parental toxins and the derived hybrid molecules would also help in broadening the use of agents 
specifically potentiating cytosolic delivery of these chimeric toxins. Amongst the most promising 
approaches are the local IT applications [113,145,166,177,178,197] (which may also help in avoiding 
undesirable side effects due to the systemic administration) in accessible tumors, such as head and 
neck, or for the minimal residue eradication of tumor cells, after surgical removal of the primary Toxins 2010, 2   2724 
 
cancer. On the other hand, a careful selection of patients would be highly desirable for higher success 
rates to be achieved, to possibly avoid chemiotherapy regimens for those patients that could be 
predicted to resist these first choice treatments. A major challenge is still represented by the 
identification of early markers of the diseases, prognostic markers [136–139] for positive clinical 
responses to these therapies, and a particular focus in studying the mechanism(s) underlying different 
patients responses to immunotherapy in order to determine optimal selection criteria [99]. 
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